Trial Profile
A Randomized Phase II Trial of Erlotinib, Cabozantinib, or Erlotinib Plus Cabozantinib as 2nd or 3rd Line Therapy in Patients With EGFR Wild-Type NSCLC
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Apr 2024
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary) ; Erlotinib (Primary)
- Indications Carcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- 04 Nov 2016 Results of a primary analysis (n=111) published in the Lancet Oncology
- 09 Sep 2015 Results presented at the 16th World Conference on Lung Cancer
- 13 Aug 2015 Planned primary completion date changed from 1 Aug 2015 to 1 Oct 2015, as reported by ClinicalTrials.gov.